Rgenta Therapeutics Presents Preclinical Data from Lead Program, RGT-61159, a Potent and Selective Small Molecule Inhibitor of MYB RNA, Supporting its Application in the Treatment of Acute Myeloid Leukemia (AML)
WOBURN, Mass., June 12, 2025 (GLOBE NEWSWIRE) — Rgenta Therapeutics, a clinical-stage biotechnology company pioneering the development of a new class of oral small molecules targeting RNA and RNA regulation for oncology and neurological disorders, announced today the presentation of preclinical data from its lead program, RGT-61159 highlighting its potential for the treatment of a […]